Botanix Investor Centre

Botanix Pharmaceuticals is a clinical stage synthetic cannabinoid pharmaceutical company with a targeted pipeline of dermatology and antimicrobial products. Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach. Our shareholders are valued partners in our Company, so we invite you to explore our Investor Centre, subscribe to our email updates and we will keep you updated with our progress.

Share price


Change

December 9, 2019
September 17, 2019
January 31, 2019
November 15, 2018
August 13, 2018
April 9, 2018
November 13, 2017

Latest video

“The Superbug Era” – ABC documentary

Addressing the pressing global emergency of antimicrobial resistance…

Australian medicinal cannabis revenue tipped to reach $200 million in 2021

Australian medicinal cannabis revenue is tipped to double this…

Rosacea Study Approval

Papulopustular rosacea is a highly visible and distressing chronic…

Progress Report for Australia’s First National AMR Strategy

The Australian Government has published the Final Progress Report…

Presentation: ASX Small and Mid-Cap Conference

Botanix Pharmaceuticals President and Executive Chairman, Vince…

ScoPo’s powerplays: Jazz Pharma’s $9.4b deal highlights pot plays

'A huge acquisition in the international medical cannabis sector…

Endpoints News | Jazz vaults into the cannabinoid field with $7.2B GW Pharma buyout

GW Pharma $GWPH, the UK biotech that caused a sensation of sorts…

Interested in investing? Check out our latest investor presentation.

Sign up to receive our latest news.

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere